maia

We have been on an absolute heater with powerful ideas lately.

Can we do it again? Let’s find out. Today’s “tactical” idea is…

 MAIA Biotechnology, Inc. (MAIA)

One of this year’s top small-cap performers is off to the races again this morning in early trading…

Make sure you get MAIA on your radar right away.

If today’s early action is any indication, today could be exceptionally exciting for the stock.

Look at where MAIA is right now… 

The stock is tapping once again on a key resistance level.

If that breaks today, then we could have a front-row seat for some very exciting action today!

👉  MAIA is TODAY’S #1 ALERT 👈

Here are some details about the company itself…

MAIA is a clinical-stage biopharmaceutical company exploring genuinely groundbreaking cancer treatments.

Its lead asset — called THIO — “is the only direct telomere targeting agent currently in clinical development.”

Its action in cancer treatment has been featured in renowned publications such as Cancer Cell and Nature.

Here’s how it works…

There’s an enzyme called telomerase that’s present in 85% to 90% of human cancers and that “contributes significantly to the proliferation and reproductive immortality of cancer cells.”

According to the company, “THIO is recognized by telomerase and incorporated into telomeres in cancer cells. Once incorporated, THIO compromises the telomere structure and function, leading to ‘uncapping’ of the chromosome ends and thus resulting in rapid tumor cell death.”

On top of killing the cancer cells directly, THIO — coupled with an immune checkpoint inhibitor — seems to produce an immune memory specific to cancer cells “where the immune system [continues] to be active against the cancer cells after extended periods of time, with no additional treatment.”

If you know anything about cancer, you know that maintaining remission is the truly critical part of therapy, and THIO is showing promise in that respect.

On February 22, MAIA announced the completed enrollment of its Phase 2 clinical trial for THIO in cases of non-small cell lung cancer (NSCLC), noting that “preliminary data has demonstrated unprecedented rates of disease control and response to date.”

And on June 4, the company revealed new data on the trial, including a favorable overall response rate of 38% and a disease control rate of 85%.

MAIA CEO Vlad Vitoc said, “All exceptional measures of efficacy in our trial to date have exceeded our own expectations and outperformed standard of care treatments.”

He added that the data “advances THIO’s excellent clinical profile as a strong, safe, and highly effective alternative for patients who progressed following chemotherapy and other available treatments.”

A July update noted that “Treatment with THIO followed by cemiplimab has been well tolerated throughout the trial, with much lower toxicity compared to standard-of care treatments.”

As of September, the company says the Phase 2 trial is “nearing completion” and that it expects long-term data before the new year.

And just on Tuesday, MAIA announced it will be detailing new updates from the trial in an oral and poster presentation at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer…

The presentation takes place very soon and the poster will be made available on this page at that time.

Folks, biotech companies don’t present new data at prestigious conferences unless the data are impressive. I take this as a great sign and it could lead to big price action in the stock tomorrow.

MAIA notes that NSCLC is “the largest tumor type globally by mortality (1.7 million deaths annually) and dollar sales ($34 billion annually).”

But it appears that THIO may prove effective well beyond NSCLC…

For instance, it has been granted three Orphan Drug Designations (ODD) by the FDA for “hepatocellular carcinoma (the dominant histology of primary liver cancers, ~90%), small cell lung cancer (the deadliest type of lung cancer), and malignant gliomas (the deadliest group of brain cancers, including glioblastomas).”

These designations afford the company seven years of U.S. market exclusivity after drug approval and tax credits for qualified clinical testing.

In upcoming clinical trials, MAIA will be pitting THIO against the likes of small-cell lung cancer, liver cancer, and colorectal cancer.

On top of all this, MAIA is developing a second generation of THIO-derived drugs. They’ve advanced more than 80 to date, with three U.S. patent applications.

According to the company, “Preclinical studies of several of these agents have shown highly significant anti-cancer efficacy at low dose levels in multiple in vivo and in vitro models.”

For a more detailed breakdown of MAIA’s trial progress and drug pipeline, check out this press release that the company put out on June 6 detailing year-to-date progress.

Company insiders have been scooping up MAIA shares hand over fist over the past week, with director Stan Smith purchasing $250k worth, director Steven Chaouki buying $55k worth, and director Ramiro Guerrero grabbing $222k worth.

Do you think they may be front-running some excellent news? Reminder: The company has a big presentation that includes new data dropping tomorrow.

Beyond that, in September, Noble Financial reiterated a $14.00 12-month price target on the stock, marking a 600% increase from its current price, as you can see from this chart:

Folks, you need to do your homework on MAIA immediately, beginning with the company website and this investor presentation.

As always, be sure to approach your trading in a responsible manner. Trading is very risky, and nothing is ever guaranteed, so never trade with more than you can afford to lose. 

Please read the full disclaimer at the bottom of this email as well so you are aware of additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

Jeff Bishop

*Just so you know, what you’re reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let’s be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren’t what you’d call “typical.”

Just a quick heads up about this ad you’re reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we currently have received fifteen thousand dollars (cash) from Legends Media for advertising MAIA Biotechnology, Inc for a one day marketing program on December 16, 2024. Previously, we received twenty-five thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program on November 7, 2024, and also twenty-five thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program on July 9, 2024 and also fifteen thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program on June 13, 2024. Previously, we received twelve thousand five hundred dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program on June 7, 2024. Also, we were paid fifteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising MAIA Biotechnology, Inc for a one day marketing program on March 6, 2024. We were also previously paid fourteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising MAIA Biotechnology, Inc from a period beginning on November 15  through November 18, 2023, and also fifteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising MAIA Biotechnology, Inc from a period beginning on October 12 through October 13, 2023. These amounts were paid by someone else not connected to MAIA Biotechnology, Inc. It might be obvious, but whoever paid for this might own shares and is likely looking to sell some or all of them at any time after we send out this information, which might affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither RagingBull nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as our program ends, though that is not always the case.

Now, diving right into MAIA Biotechnology, Inc might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there’s exceptional risk involved in trading. This isn’t small potatoes we’re talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We’re shining a light on the good stuff about the company here, but it’s on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.

Oh, that brings us to another crucial point—we’re not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can’t wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who’s licensed to give you real advice. To be clear, 

Neither Raging Bull nor its owners, employees, or independent contractors are registered as a secur1ties br0ker-dealer, br0ker, 1nvestment advis0r (IA), or IA rep’s with the SEC, any state securities regulat0ry authority, or any self-regulat0ry organization.

So, that’s the scoop! If you’re intrigued and want to learn more about the companies we talk about, hit up the SEC’s website to dig into their filings and see the full picture.